Guggenheim Cuts Immunovant (NASDAQ:IMVT) Price Target to $44.00
Immunovant (NASDAQ:IMVT – Get Free Report) had its price target dropped by equities researchers at Guggenheim from $46.00 to ...
Immunovant, Inc. (NASDAQ:IMVT) Shares Bought by KBC Group NV
KBC Group NV boosted its position in shares of Immunovant, Inc. (NASDAQ:IMVT – Free Report) by 60.1% in the 4th quarter, ...
Immunovant’s Promising Pipeline: Strategic Advances in FcRn Inhibitors and Market Expansion
Analyst Sam Slutsky of LifeSci Capital maintained a Buy rating on Immunovant (IMVT – Research Report), retaining the price target of ...
IMVT Q3 Loss Wider Than Expected, Stock Down, Pipeline in Focus
Immunovant stock down on dismal third-quarter fiscal 2025 results. It is on track to initiate 10 studies on IMVT-1402 across various autoimmune indications.
Immunovant’s Strategic Advancements and Market Potential Highlighted in Buy Rating
Analyst Brian Cheng of J.P. Morgan maintained a Buy rating on Immunovant (IMVT – Research Report), with a price target of $46.00.Invest with ...
Amgen Inc. (NASDAQ:AMGN) Q4 2024 Earnings Call Transcript
Q4 2024 Earnings Call Transcript February 4, 2025 Amgen Inc. beats earnings expectations. Reported EPS is $5.31, expectations ...
Immunovant's chief medical officer Michael Geffner sells $62,678 in stock
The transaction was conducted to cover tax withholding obligations related to the vesting of restricted stock units, as mandated by the company's policies. With the company's next earnings report ...
The Villager13d
Soleo Health Unveils Ambulatory Infusion Suite in Denver
Denver Location Boasts Private Infusion Suites for Addressing Patients’ Specialty Therapy Needs Soleo Health, an innovative ...